share_log

Emergent BioSolutions Analyst Ratings

Benzinga ·  Aug 29, 2023 06:38
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/29/2023 Benchmark Downgrades Buy → Hold
05/31/2023 397.74% Benchmark → $22 Reiterates Buy → Buy
05/19/2023 397.74% Benchmark → $22 Reiterates Buy → Buy
04/10/2023 397.74% Benchmark → $22 Upgrades Hold → Buy
03/17/2023 103.62% JP Morgan $23 → $9 Downgrades Neutral → Underweight
11/10/2022 Benchmark Downgrades Buy → Hold
11/09/2022 1144.34% Chardan Capital $65 → $55 Maintains Buy
09/12/2022 556.11% Cowen & Co. $30 → $29 Maintains Market Perform
05/04/2022 759.73% Wells Fargo $46 → $38 Maintains Equal-Weight
04/29/2022 1370.59% Chardan Capital $75 → $65 Maintains Buy
03/10/2022 804.98% Wells Fargo $37 → $40 Maintains Equal-Weight
11/10/2021 1596.83% Chardan Capital $92 → $75 Maintains Buy
11/08/2021 Benchmark Downgrades Buy → Hold
05/05/2021 Argus Research Downgrades Buy → Hold
04/30/2021 1981.45% Chardan Capital $112 → $92 Maintains Buy
04/07/2021 3293.67% Benchmark → $150 Initiates Coverage On → Buy
02/24/2021 2433.94% Chardan Capital → $112 Upgrades Neutral → Buy
02/19/2021 2433.94% Chardan Capital → $112 Downgrades Buy → Neutral
01/08/2021 Wells Fargo Downgrades Overweight → Equal-Weight
07/31/2020 2433.94% Chardan Capital $86 → $112 Maintains Buy
07/17/2020 2388.69% Cantor Fitzgerald $85 → $110 Maintains Overweight
06/08/2020 1823.08% Cantor Fitzgerald $86 → $85 Maintains Overweight
05/06/2020 1936.2% Argus Research $67 → $90 Maintains Buy
05/01/2020 1845.7% Cantor Fitzgerald $75 → $86 Maintains Overweight
05/01/2020 1845.7% Chardan Capital $71 → $86 Maintains Buy
04/30/2020 1823.08% Wells Fargo $75 → $85 Maintains Overweight
02/25/2020 1596.83% Wells Fargo $66 → $75 Maintains Overweight
09/12/2019 1370.59% Guggenheim → $65 Initiates Coverage On → Buy
09/04/2019 1347.96% Wells Fargo $61 → $64 Upgrades Market Perform → Outperform
11/02/2018 1596.83% Cantor Fitzgerald $68 → $75 Maintains Overweight
11/02/2018 1596.83% Goldman Sachs $60 → $75 Upgrades Neutral → Buy
09/04/2018 1393.21% Chardan Capital $60 → $66 Maintains Buy
08/30/2018 1370.59% Wells Fargo $61 → $65 Maintains Market Perform

What is the target price for Emergent BioSolutions (EBS)?

The latest price target for Emergent BioSolutions (NYSE: EBS) was reported by Benchmark on August 29, 2023. The analyst firm set a price target for $0.00 expecting EBS to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Emergent BioSolutions (EBS)?

The latest analyst rating for Emergent BioSolutions (NYSE: EBS) was provided by Benchmark, and Emergent BioSolutions downgraded their hold rating.

When is the next analyst rating going to be posted or updated for Emergent BioSolutions (EBS)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Emergent BioSolutions, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Emergent BioSolutions was filed on August 29, 2023 so you should expect the next rating to be made available sometime around August 29, 2024.

Is the Analyst Rating Emergent BioSolutions (EBS) correct?

While ratings are subjective and will change, the latest Emergent BioSolutions (EBS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Emergent BioSolutions (EBS) is trading at is $4.42, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment